Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Eculizumab Dosing Intervals Longer than 17 Days May Be Associated with Greater Risk of Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria
PaperCitations, authors & open-access status
Eculizumab Dosing Intervals Longer than 17 Days May Be Associated with Greater Risk of Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 44 citations, 2016 year and diamond oa status.
44
Citations
2016
Year
diamond
OA Status